YouTube Transcript:
RUMA Agri Webinar 1 2025 Opportunities & Challenges Influencing the Responsible use of Medicines

Skip watching entire videos - get the full transcript, search for keywords, and copy with one click.

Video Transcript

Video Summary

Summary

Core Theme

This webinar, hosted by Rumor Agriculture, focuses on the opportunities and challenges influencing the responsible use of medicines in livestock, emphasizing the UK's leading role in tackling antimicrobial resistance (AMR) and the importance of maintaining high animal health and welfare standards for trade, consumer confidence, and overall farming efficiency.

Mind Map

Click to expand

Click to explore the full interactive mind map • Zoom, pan, and navigate

Good morning everyone and welcome to

today's rumor webinar. My name is Cat

Welcome and I'm the chair of Rumor

Agriculture and will be chairing the

session today. First things first,

there's just a few bits of housekeeping.

Um say this webinar is being recorded

and it will be published on the Ruma

website in due course.

Please can I request that you mute your

microphones and turn off your cameras

for the duration of the webinar. Um that

would be really helpful and it would it

would help to um not create any distractions.

distractions.

We have a lot to get through and a lot

to discuss today, which means that there

won't be specific time for questions

from the audience. But if you do have

any burning questions, please feel free

to add them to the Q&A function. And if

we have time, we will answer a few. The

chat function has been turned off. Um,

so as I say, it's just if you have some

burning questions, please add them to

the Q&A function.

Our webinar today is entitled

Opportunities and Challenges Influencing

the Responsible Use of Medicine and is

the first in a series of four live

webinars that Rumor Agriculture is

delivering throughout November. The

other webinars, if you'll just indulge

me to quickly share details, are the

future for vaccine availability for the

UK animal health market. And that's on

Wednesday the 12th of November from

11:00 to 12:30 p.m. And in that, we'll

hear the results from the vaccine

availability survey that Rumor ran

earlier this year. And there's also a

VMD presentation and a Q&A with the BMD.

The next webinar is um the rumor

agriculture agriculture targets task

force 2 final report and the bars report

launch and that's Wednesday the 19th of

November from 11:00 to 12:30 p.m. So

that will see the release of the latest

BMD's bars report plus the release of

the final report in the rumor cycle of

targets. That's the uh TTF2 report. And

then the final webinar is the um rumor

target task force 3 launch and that's

Wednesday the 26th of November from

11:00 a.m. until 12:30 p.m. And at that

we'll unveil details of the third cycle

of sector targets.

We of course hope you can join us at all

of the webinars but if not as I say they

will all be available to watch again on

our website in due course.

So back to today and our focus is on a

panel discussion on the opportunities

and challenges influencing the

responsible use of medicines and I'm

delighted to be joined by a fantastic

panel of experts.

Just by way of introduction, I would

like to ask you all to introduce

yourselves and who you represent and

answer the question what the responsible

use of medicines means to you and your

organization from the perspective of

your role. And I think I'll kick off

>> Hi Cat, morning everyone. Thank you so

much uh for inviting me to be here. I'm

Abby Seager. I'm the chief executive

here at the veterary medicine's

directorate um and I have therefore

policy and operational delivery

oversight uh for veterary medicine's

regulations um and antimicrobial resistance

resistance

in relation to the question what does

responsible use of medicines to me mean

to me I mean I think the the word

responsible is absolutely imperative um

but maybe from three specific angles for

me one being protecting animal health

and welfare so that medicines are used

when necessary and at the right dose and

under professional guidance in order to

maintain high healthare standards.

Secondly, responsible use means

preserving efficacy and reducing

resistance to safeguard the

effectiveness of of medicines for for

future generations.

And thirdly, it's about responsible use

of medicines in balancing health and

environmental responsibilities which of

course is informed by by good evidence.

So those are the three aspects I would

say responsible use of medicines means

for me.

>> Thank you >> Clara.

>> Clara.

>> Hello. Uh good morning everyone and

thank you for inviting me to be part of

this panel. Um so I'm Dr. Claraara

Savile. I'm the veterary head of exotic

disease uh at the animal and plant

health agency and I'm going to address

this question from the perspective of

the agency but also from my role on the

exotic disease side. So um firstly APA

plays a really important role in the

prevention of disease and that's both

endemic and exotic of course working in

partnership um with uh farmers and

others and so that reduces the reliance

on antimicrobial use by uh preventing

disease. Um secondly, APA has a

complement of national and international

uh reference centers including a AMR uh

global uh reference center and that

really highlights the expertise that we

hold uh within APA. Um and APA conducts

cutting edge research on antimicrobial

resistance and this better equips us and

others in tackling AM AMR and

antimicrobial use. And finally, APA uh

undertakes AMR surveillance working very

closely of course with uh VMD. Uh that

surveillance is conducted in diseased

and healthy livestock and this is all

published in the VARS report which will

be launched imminently. Um and that data

shows an association between reducing

antimicrobial use and reducing

antimicrobial resistance.

Thanks K.

>> Thank you. Carl, you want to go next?

>> Hi, good morning everybody. Um, my name

is Carl Dumashi Servas. I lead something

called Health for Animals and that's the

the global trade association which

brings together all of the producers of

animal health products around the world.

So, producers of vaccines, parasite

control products, antibiotics,

diagnostics and all the other tools both

for livestock and for pets. We represent

11 of the largest 11 companies around

the world and another 100 plus smaller

companies through our national

associations and you will all know Noah

in the UK which is our UK association.

So we estimate that we uh represent

about 85% of the total value of products

produced around the world and I'm I'm

I'm here because I'm going to take a

slightly more international perspective

today if I may. Madam Chair, um to your

question, what is responsible use? I

think I agree with the definition that

uh Abby gave. Um product use that meets

three conditions for us. Use for animal

welfare. So that animals that are

treated that animals are treated

promptly and don't have any unnecessary

suffering when necessary sick animals or

at risk animals. And of course with

veterinary oversight uh and and um I

think um I think you said all the the

right words, the right product, the

right dose, the right route and the

right duration. Thank you.

>> Thank you. And I'll come to Gavin next please.

please.

>> Thanks C. Morning. Um I'm Gavin Morris.

I'm coming today with a with a probably

a few different hats on. Um so I'm an

exfarm vet. But I sit on the steering

committee of the food industry

initiative on antimicrobials which is a

grouping of retailers and and food

service and processors with a with a

common common aim

sit on the governance and group of the

AHDB medicine hub and I'm president of

the veterary public health association

and my sort of day job is group primary

technical animal welfare and veterary

manager for Dumbia door meat um which is

probably one of the largest beef and

sheep processors across UK and Ireland

and and a very large exporter which for

us is really important. So from a an FIA perspective

perspective

the FIA members they would very happily

have use of a national usage data

national usage figures but the longer we

don't have those the more the pressure

grows from the retailers and food

service to require their own data.

From a medicine hub perspective,

Wales have been really successful in

populating their own Welsh usage data on

their system. Scotland are closing in.

They're close behind and Northern

Ireland behind that. But there's a real

concern that English ruminant data,

especially beef and sheep, you know, is

lacking despite the efforts of the

medicine hub to provide a platform for

it to go onto. EM pigs worked, but we're

not yet there for ruminance.

And then lastly, I think from a a

veterary public health association

perspective, you know, we're that

represents public health vets and and

particularly vets working in

certification for export. And it also

links very much to my day job with

Dumbia Dawn and our real concerns that

the risk to future exports from the lack

of, you know, demonstrable antibiotic

responsible use or usage data. So there

would be a number of different angles

that I'm coming at this today. Thanks C.

>> Thank you. And Jonathan,

>> morning cat. Thank you. Uh morning

everybody. Well, I um I probably just

described sort of four different roles

and answer very sort of swiftly across

those four. So the first thing is I'm

coming up to 30 years as a cattle vet in

practice. So bishops and vets in North

Yorkshire. Um uh secondly, I'm been

chair of animal health and welfare board

for England for the last four years.

I've been on the board say nearly eight

now. Basically, um advising ministers

and senior officials on all policy to do

with kind of kept animals. Thirdly, I'm

chief exe of ag biotech company looking

at developing technologies in the whole

area of sustainable food. And finally,

I'm professor of sustainable lives

health and welfare at Harp and Kilbert

School. So to pick up your thing which

as you know is something that I care

about you know really kind of

passionately I think responsibility to

medicine across those four areas. First

of all I'm a prescriber. So basically as

a vet in practice the farmers animals

under my care medicines are at the heart

of really looking for animal health and

welfare. So that's the first thing is

crucial. The second bit from a policy

perspective is looking at what you know

medicine's meaning in terms of animal

health and welfare policy. and one

health and food security and all those

aspects around where we interact really

with kind of medicines and all those

aspects. The third bit is in terms of

with raft is looking for technologies

that actually allow us to innovate for

the UK to innovate and to prevent

disease to have healthier animals is

really key. And lastly from a vet school

perspective is actually looking ahead

the next generation. So education

embedding responsible use in medicines

from year one for veterary

undergraduates and also being part of

kind of research in looking for really

future innovation to actually have

responsible use.

It's me.

>> Thank you. So let's get into some more

of the detail. It's important to

acknowledge that there are many factors

impacting the responsible use of

medicines and livestock. But what is

clear is that the UK has been leading

the way when it comes to responsible

stewardship and in particular it's

worked to tackle AMR and this has seen a

voluntary 59% reduction in the use of

antibiotics over the past decade.

This has seen the industry focus efforts

to the point that stewardship is now

embedded into the daily work of the

livestock industry. And whilst the

responsible use of medicines is key to

helping to protect the efficacy of all

medicines and help reduce the prevalence

of resistance, there are also other

important factors associated with

responsible medicine stewardship. Be

that for trade purposes, consumer

confidence to continue to demonstrate

the UK's high health and welfare

standards in farming or to simply ensure

good animal health in our enterprises

which helps drive um efficiency.

All of these are essential factors in

making sure that UK farming is viewed as

the best, as leading the way, and is

recognized as a principal contributor

and driving force in the battle against AMR.

AMR.

I think it's fair to say that the UK has

real strengths, measurable reductions in

antibiotic use, and strong industry

leadership frameworks and a national AMR

action plan. But there is still an

ongoing need for coordinated action to

sustain responsible medicine use while

protecting animal welfare.

So let's now talk about the

opportunities and challenging and

challenges influencing responsible use.

And I'll come to my first question.

Gavin, we always talk about the UK

having some of the highest health and

welfare standards in the world. Do you

feel that this statement is still

justified and does it offer us any

>> Thanks, K. Um, yeah, I think that's a

really good good question. Um, and I

think look, I think there's an awful lot

of good practice and that we should be

very proud of it across the UK, but I do

think it would be perhaps wrong to think

that no other countries also have high

standards. Ireland, many countries in

Europe, many other world third

countries, Canada, New Zealand, New

Zealand quality lamb. So I think we need

to be mindful that we've got a lot of

good things, but you know, we're not

alone. You know, there's a lot of other

countries are on this same path, this

same game. You know, I'm going to sort

of really focus the rest of this, I

think, really on the animal health side

and antibiotics and and perhaps look at

this from um an export perspective.

Maybe to give a different different view

um of this away from just what happening

at farm level and where this all fits

in. you know, huge huge volumes of of

meat and especially awful, you know, is

exported from the UK. And that trade's

really really significant for UK farming

for now and in the future. And it's that

it's that latter bit that I think we're

we're becoming more and more worried

as as a country, as you said, you know,

anti victim reminance, but other

countries are catching up. other

countries have caught up and other

countries actually probably are ahead of

us. So we say we're good but in some

aspects some sectors in the ruminant

piece we we just can't quite prove it.

We can't properly prove it. Some of our

other proteins have the data but in

ruminance we don't yet. You know

antibiotic use data sure many people

will know it's now a legal requirement

in the EU and it is collected in

increasing numbers from other world

third countries. for example, Canada,

you know, and they're using it to

support their trade efforts. So, other

countries have really gras grased it,

you know, exports are really important

for them too. You know, it's success of

their livestock and meat and farming industries.

industries.

If other countries have the data, but we

don't, you know, our worry is that is

that potentially going to become a

blocker to export? Is that going to be a

blocker to trade? you know if one

country has and the other doesn't you

know commercially that becomes quite a

bigger risk as the world evolves you

know international meet secretariat the

secretary general many people know Phil

Hadley absolutely believes that this is

a real risk as well you know the world

is changing you it's changing in ways

that we we we can't predict it's very

unstable you know increased supplies are

coming from all over the world you know

Eastern Europe Australia New Zealand uh

America America, you know, and a lot of

it's of excellent quality, you know,

those countries, you know, and others,

they are our direct competitors for our

meat and our um export offer markets.

You know, we're in direct competition

for that. So, we are leading, as Cat

said, I think we are leading in lots and

lots of ways, but that apparent

reluctance at the moment in the ruminant

sector for us is is proving really

worrying. you know, once those export

contracts are lost, if they were to be

lost, that's really hard to get them

back. If you've lost it, you're

struggling. You're not going to get

those back easily. And commercially, I I

do I keep getting asked, you know, what

are we hiding? You know, why can't we

show usage when other people can and

more and more countries can, you know,

what we hiding? You know, we all think

we're not and we we're not, but we're

not showing it yet.

So I think without our exports you know

the ruminant sector would look

incredibly different if that root of the

meat and awful at the end of it is not

there you know all the rest of it just

you know that's going to struggle it

wouldn't be there in the same shape it

is now um so I think really concluding

really cat I think just just thinking

we've got the highest standards just

isn't really enough anymore you know

we've got to be able to show it so it is

a real plea from the export sector that

everyone does come behind

you know, we come behind antibiotic use

data, you know, and and and really get

on board for it. It's it's hugely important.

important.

Yeah. Thanks, K. That's that's it's

really that massive export piece and the

health piece and use of antibiotics. I

think that's critical for us.

>> Yeah. And it's it's again it's turning

that kind of that anecdotal

understanding that you know the ruminant

sector has always been a traditional low

user but being able to prove that

>> I know I think there's there's you know

think about it as I'm talking there's

there's so much within the the the meat

sector is is audited to very significant

degrees customers and and uh suppliers

that we supply to you know the the level

of audit and scrutiny is high Um, and if

we've got this little hole here where we

haven't got this data, it it's hard to

say to people that yes, it's all right

because they're saying, well, show us,

prove it. >> Yeah.

>> Yeah. >> So,

>> So,

>> and Abby, as the as the regulator, what

what's your take on on this statement

about, you know, we have some of the

highest health and welfare standards.

Where do you think the opportunities and

and challenges might be with that as a

as the regulator?

Thanks C and and thanks Gavin for your

for your take on that as well. I think

the um well hopefully you know that the

the UK's trade strategy sets out that

from a government point of view there is

no there will be no lowering of food

standards and we will up high uphold the

high animal welfare standards and we

know that that high health and welfare

standard is really critical for tackling

AMR. Um, and as Gavin referred to, we're

not the only country in the world who

has a higher standard and that's where

we want the others to be in order to to

tackle AMR from that angle. That's

exactly where uh some of our

international work is focused. Um, Kat,

you said yourself, although I'm sure you

knew I'd probably chuck it into an

answer here somewhere, that we've got

that 59% reduction in antibiotic use uh

in food producing animals over the over

since 2014. Uh, might say again at some

point. Um, and we still remain one of

the lowest prescribers. um of

antibiotics and we've achieved some

really great reductions in resistance

across Europe. So we are in a really

good place but absolutely Gavin it's not

a case of being at the very top and

looking down on others. We want others

to be there too. We also know that um

the recent public accounts committee uh

report highlighted that it's important

that we remain having a focus on AMR as

a global threat and that trade

agreements in that space don't weaken

our resilience uh to AMR.

And as I said, the trade strategy shows

that we don't want to lower any

standards and that animal welfare is is

really important. But I think there is a

definitely recognition about that that

methods of of production which are not

permitted in the UK. Uh and there are

concerns about that that there are

methods that vary in line with different

climates um and um diseases and other

contextual reasons.

that there will always be a

consideration about whether or not

overseas production has an unfair

advantage and any impact that that may

well have. Um and I know that it's from

a government point of view there will be

um when it's necessary um there will be

um an ambition to be prepared to use a

full range of powers to to to protect

our most sensitive sectors um wherever

that whatever that may well look like.

But in terms of the the international

work that we're and maintaining those

high welfare standards, uh a lot of the

work that we've been doing through our

national action plan also relates to our

international action and bringing the

providing the support that is needed to

bring those standards up globally in the

areas where there are maybe um at a at a

lower level currently. Um and um that of

course sits alongside the um the SPS and

um AMR cooperation provisions in in

various trade agreements in relation to

the challenge which is the question

here. I think there's always a challenge

to maintain standards always even if we

have an ambition to do so there's always

a challenge to do that. There's also a

challenge in relation to driving forward

those standards either in terms of uh

appreciating the environment we're

working in especially where there are

multiple influencing factors and for me

it feels like over the course of the

last five years there have been so many

factors many of which we didn't

necessarily predict some of them have

been through political changes shall I

say some of them have been through

environmental changes some of them have

been through global geopolitical changes

that we're having to factor in with all

of those challenges though Um any leader

will tell you there's always an

opportunity. Uh and of course there is

um an opportunity that however can feel

challenging perhaps for me right now

would be our our maintaining ambition to

improve our relationship with the EU and

and maybe through the SPS agreement we

can do that. We know that the EU's

accepted that there will be a number of

areas where we need to retain our own

rules. Um, and a lot of that is of

course subject to still to negotiation,

but we've been clear about the

importance of being able to set high

animal welfare standards and support

public health and support the use of new

and innovative technologies as well in

order to maintain that position. >> Okay.

>> Okay.

>> Thanks, Cat. Abby, whilst I've got you,

um, we know how important it is for

there to be a reliable access to

reliable access to and supply of all

veterary medicines,

but of course it is expensive to bring

new products to market and the process

for licensing is not easy. Is the

balance right and where are the pinch

points? And then I think maybe I'll come

to Carl after after I've heard what you think.

think.

>> Yeah, thanks Kat. And hopefully you can

see me. I've got a lovely bit of

sunshine right in my face. I'm I'm

trying to move into the sun rather than

the shade. So hopefully you can see me.

Okay, there. Um yeah, I mean I I

completely I I agree. It is absolutely

imperative that we have supply and

demand that is balanced and we know

absolutely from a problem statement that

has come to us through species groups

over the course of the last couple of

years um in everinccreasing number that

that balance is not always met. Um and

that's why the VMD recently published

our statement of intent which another

word for strategy I suppose uh for

vaccine supply but of course the

principles can be applied to all

medicines but we know the current

feeling is that vaccines themselves are

a group where uh that supply and demand

balance is currently mismatched. I know

we've got a whole other webinar on that

so I won't I won't go into the detail of

it all but it's important that um we

recognize that um where that problem

statement exists the reason for that for

that problem statement and we've been

really clear um through some of the

communication we've done either through

surveys or through the round table to

understand where those pinch points

might be and especially for me as a

regulator if they are regulatory pinch

points um we know that the industry the

pharmaceutical industry is set up to

service the EU as a region. Um, and we

therefore um follow a lot of the

international guidelines and data

requirements that will help uh retain

the UK as an attractive market for

veterary medicines. So we've doing a lot

in the space that um we are in now postrexit

postrexit

to enable that pharmaceutical industry

to still thrive in uh what has been an

ambiguous situation.

We also know that um some of the

challenges are relation not just to

bringing products to market for diseases

that we know about but it's about

emerging diseases. It's about novel

technologies that we need to consider.

How can we make sure that there is a

space for innovation that the UK is open

to um those innovative um um vaccine

developments specifically um or any

other uh medicine um and especially in a

space where if we think about what the

animal health sector looks like now and

will look like in the next 5 years. We

know for example that there'll be more

companion animals. There'll be more

elderly companion animals for example.

Um so we just need to understand what

that whole animal health sector looks

like and where we can position ourselves

as the regulator to enable that so that

there are the uh the maximum number of

products on the market and that they are

available in the supply levels that uh

demand is expecting.

I think also from a regulator point of

view uh hopefully many people will know

what what our ambition has always been

to put ourselves in a space where we can

work more globally with other regulators

uh to bring um applications to uh the UK

at the same time as to others whether

it's through a joint review process uh

with Canada or with Australia and

Switzerland. Uh we're working on

agreements with the US. um it provides

lots of opportunity for particularly for

multinational companies to uh to bring

to bring products.

I re recognize that one of the one of

the fundamental differences really

between veterary medicines and and human

medicines to which we are very oftenly

uh compared is the involvement of the

NHS and wouldn't it be wonderful if

there was an NHS for animals uh but

there isn't and so there isn't that

guaranteed purchasing power

[clears throat] that the government has

on the human side uh and we do not have

that on the on the animal side um

so understanding where the problems come

from especially um those that are within

my remit and I wish all of the problems

were within my remit and therefore I

could solve them all but I I I can't. Um

but I will be in a position to um be a

conduit to what some of those problem

statements are and those pinch points

are so that we can then look at what can

be done to address those because

ultimately the ambition is well um

agreed and understood and of course at a

ministerial level as well that we want

to ensure that we have all the products

we need for all of the markets that need

them at the right time which of course

then sings to the need for uh

responsible use of products. Okay. Um

Carl, um I'd like your thoughts on on

this same question if if that's okay. Um

>> it's okay.

Um yeah, maybe worth making a couple of

points here. So um

I think firstly it's it's good to

understand that very few companies take

a solely national look. I think Abby

alluded to this when they develop when

we develop products or or or or uh or

our sales we need to have nowadays you

need to have multiple larger markets to

make it worth the investment. So very

few companies will look only at the UK

or only this market or that market. They

look at at multiple markets when they

develop products. Another point which is

relevant for people to understand I

think is that most most large animal

health uh product uh uh developers most

companies they develop both livestock

and companion animal products and so

there's only so much investment there's

only so many pounds or dollars or euros

which can be spent and so there is it is

fair to say that there is a competition

between investment into livestock

products or into companion animal

products and that's the reality of the

market. um and you know the the the

economic dynamics of those two are very

different. Now about actual cost I think

it's also fair to say that it is costly

to devel to develop new products and to

get them onto market but but but the

needed investment we measure that

against potential revenue obviously and

the higher the costs the more

challenging it is to make the case to

invest. So in our sector it's really

important to realize that the highest

cost input for us is regulatory

requirements and that's generating data

testing of the products to to show

efficacy quality and um and safety and

and you know the associated staff which

goes with that. So that's the highest

cost. Now as Abby talked about in the

case of the UK since a couple of years

we have this this added complexity of

having to apply for licenses separately.

uh compared to you know the situation

before um and and any divergencies there

in terms of requirements particularly

technical requirements can can I I say

that I choose that word very carefully

create regulatory complexity and that

does have an adverse impact on decisions

on where to invest and the economic

viability of our products. So we we

strongly believe that some sort of

agreement, some sort of veterinary

medicine agreement should be made

between the UK and the EU to to

facilitate this continued, you know,

technical convergence of of these

products throughout the regulatory

process. and and in staying you know as

aligned as possible in that process

would ensure and let me be very clear

about this this will help to ensure

long-term availability of medicines.

The less discrepancy there is between

veterinary regulatory processes and

requirements, the easier it is to make

the case internally to keep us on

markets uh and to put them on market. So

maybe two other additional points. Um um

we like a wellresourced regulatory

authorities. You have a good one in VMD,

a very good one in the UK. You're lucky.

Can't say that for other markets, many

all other markets. Um, but we would

certainly urge you and I think everybody

on this call as well to realize that and

to make sure that the increased public

investment that's needed uh is there.

That's a plea. Make sure that you have a

good continue to have a good regulator,

well resourced one. That's important.

And lastly, I think uh maybe just

completely different point um getting

products to market. We've got this AI revolution.

revolution.

There are so many wonderful

opportunities both within uh our

processes internally in companies but

also within the regulatory processes to

look at how under human guidance uh we

can use AI to to to to get products to

market easier, faster, better, cheaper.

Um so so I think there are real

opportunities there uh to get

innovations to market. Thanks C.

>> Thank you. So I suppose really I mean

what we've talked about there is a bit

it's a bit around the supply and demand

isn't it and part of that demand

equation is looking at some of the other

externalities that's that's developing

as well. So just want to change t

slightly and I'm looking at Jonathan I

think um first Jonathan

change how do you think the change in

climate will affect our approach to to

medicine use?

Thanks K. I think I mean there's so much

here, isn't there? I mean first of all

and let's just think about what you know

new emerging disease threats you know

look like associated with climate change

in the environment. I mean we can think

about very immediate examples of blue

tongue. Um you know as we see climate

change brings vectors for disease that

couldn't really thrive in in our climate

that as that changes potentially can. So

we see movement north, east, south, west

from existing disease reservoirs that

things move. So I think climate change

presents challenges if new emerging

pathogens that weren't threats before

become threats and that means therefore

you know demand for new vaccine

development for new therapeutics for new

preventative in particular.

So I think that's particularly kind of

key isn't it with things like insect

vectors and emerging parasites. I mean

even to the degree that you know in the

east of the country I didn't used to see

liver fluke 20 years ago you know

basically in the east of England and as

things have got wetter and we now see

parasite challenges that weren't there

are actually now kind of much more

widespread. So I think we're going to

see globally new emerging disease

threats as well as regionally and

locally those changes. Parasites are

very particular. Are we going to see

kind of tropical um you know kind of

parasite threats that we haven't seen in

kind of you know northern temperate

climates emerge. So they all bring with

them needs for new medicines um for

innovation to produce both new vaccines

but also new therapeutics.

But I think it goes beyond that as well

doesn't it? If we think about what you

know climate change can mean whether

it's flooding or drought and in terms of

antimicrobial resistance. If we look at

what it means for spoilage and basically

animals that are um exposed to to sewage

and runoffs um because of flooding means

that we get a whole interaction between

animal and human and environment that

comes with flood challenges. And in the

same way the opposite with drought where

we get heat stress effects on animals

but also on plants we get different

micotoxin aphletoxin challenges in

drought um you know kind of ridden crops

that have an impact on animals. So I

think climate changes bring this really

complex set of of of challenges that all

bring with them a demand for innovation

around medicines and they all bring

challenges around antimicrobial

resistance because they drive animals

and humans and environment closer

together quite often in that

interaction. But I want to also perhaps

cat just also flag the massively

important role of livestock in food

security in being able to adapt to

climate change. You know ruminants all

around the world are a massive massive

insurance factor. We can move ruminants

in particular away from flooded areas to

kind of to to dry ground or we can move

them away from drought areas towards

water. So globally animals are really

really important in actually adaptation

to climate change. So I think we've got

to recognize that they've got a really

positive role as well as recognizing

that farming and animals are part of a

global responsibility to reduce you know

the impact you know um both greenhouse

gases and warming but also recognizing

you know biodiversity in terms of

pollinators understanding our

responsibilities for that bigger picture

of food the environment and kind of

human animals means can we use precision

approaches to reduce the impact on the

environment in how we we use our

medicines responsibly. So, I think I'll

I'll leave it there, Cat. But it's it's

a complex sort of two-way picture, I

think, where, you know, farming animals,

we've got our share of responsibility

for um impact the environment, but we've

also got a huge opportunity to continue

to adapt both with medicine's

innovation, but also find animals to

supply food. And actually, you know, the

great thing about organic um manure

fertilizers is what they do for soil,

what they do for actually, you know,

sequestration opportunities. So,

livestock have got a really positive

role to play actually in being some of

the mitigation for um climate and

environment challenges.

And Claraara just coming to your you

know your area of expertise.

Do you think we have the right

mechanisms to identify those new

emerging diseases and those challenges

and can responsible medicine use adapt

and provide industry with the the right

>> Thanks C. And just to follow on from

what Jonathan was saying, um, climate

change, global heating, an AMR are two

global challenges that are absolutely,

um, interlin. Um, in response to your

part of the question about do we have

the tools to respond, I'll I'll talk

about AMR first and then my uh more uh

from my side of things from exotic

disease control. But in terms of AMR,

uh, APA, there are team of amazing vets

and scientists who are working on

antimicrobial resistance. Uh, and we're

part of the, uh, UK national action plan

to confront AMR. Um, and as part of

that, there's a crossgovernment program

called Path Safe, which is about

pathogen surveillance in agriculture,

food, and the environment. And this

really focuses on improving the

detection and tracking of of food born

uh human pathogens and associated AMR

from looking at the whole chain from

farm to fork. So that's just one example

of how uh we're prepared from the uh AMR

site and of course as I said there's um

surveillance conducted all the time that

is published in the AMR report and the

teams of scientists uh um vets can

respond and support um when we find uh

cases of antimicrobial resistance on

farms. Moving to the exotic disease side

and as Jonathan has said we've got an

awful lot of exotic diseases sort of

stacked up on our doorstep in Europe and

those include these uh vectorbor

diseases. We have been dealing with blue

tongue sweeping across uh the country.

Um uh lumpy skin disease on the on the

doorstep in in France um Italy and Spain

and uh of course western virus uh as

well. um all um uh vectorborn diseases

which through blue tongue we have

realized they're really difficult to

control from our traditional methods of

um uh movement controls or stamping out

through culling and therefore we have to

have this uh we've shifted to the

strategy of of vaccination being our our

best controlled strategy um at the

moment and and then of course we look to

Carl and and his colleagues needs to

support us to supply

the um uh uh vaccinations

um and the vaccines and bring those in.

Just while we're on vaccines, there can

be obstacles to for bringing that in, we

have trade implications uh to consider.

for example, we're piloting a influenza

um vaccination with a a small pilot and

as we've seen in France, that can have

trade implications. We've got to think

about vaccine supply and then there's

also public perception around uh

vaccines shifting and and changing that

we need to certainly be aware of

possibly respond to. Um, in terms of do

we have the mechanisms to respond to new

and emerging diseases? Well, on exotic

disease, we work to the contingency plan

that really sets out clearly um uh how

we detect and respond. We've had a lot

of practice uh recently with responses

to aven influenza and and blue tongue.

It really is a a welloiled machine in in

terms of that response. And we have

expert epidemiologists that I work very

closely with in APA who are tracking

disease internationally uh leading

surveillance programs across the

country. Um and and my teams um respond

to any report cases. Um detecting and

responding to exotic disease early is

really essential and we have fantastic

teams of uh vets and scientists who do

that at APA.

But the National Audit Office report has

stated that this is something that we

need to work on in terms of our

strategic long-term response, how we

prepare for the next big one. Um, and

the the constant response to avian

influenza and blue tongue um has meant

that resources have been focused on on

that as an agency. um it the capacity to

do both things is uh has been noted by

the national audit office that we the

capacity isn't there to do that. So

that's something that we're working on

um as an agency um to better focus on. Um

and uh I I think also just looking at

both exotic and endemic disease, the

importance of biocurity and how we can

all work together as as a a a team

really and that biocurity

can really help with both exotic

disease, endemic disease. um reduce the

disease burden overall

um and and therefore lead to less

reliance and and use of uh antimicrobial medicines.

medicines.

I'll stop there.

>> Thank you. And I just want to open this

up a little bit and I I'll ask I'll ask

Gavin um afterwards about consumer

opinions, but I'm just thinking I mean

there's um you mentioned Path Safe um

which I think is a fantastic initiative

um you know and so I would I would

encourage anyone anyone in the audience

to go and have a look at you know and

find out what Path Safe is and and read

up some of the some of the information

about it. But I was just quite keen to

understand maybe coming back to you a

bit Jonathan

with vaccines and certainly with things

like blue tongue we've seen there are

there are mixed messages out there

between you know farmers and some vets

on the ground.

Are we are we doing the right things to

try and get those messages out there

that vaccines when they go through all

those pro the licensing process that

they they've gone through that they are

safe providing they're used in the right

way or where do you think we need to we

need to kind of slightly improve on that

to encourage uptake?

>> Thanks K. I think um again building on

what Clara said I think the teamwork

aspect of this is absolutely essential.

I mean I'm speaking as a a vetting

practice as well as kind of you know a

policy role with our health and welfare

board. We need to be really well joined

up here in getting consistent messaging

out. There's some great work that kind

of you know rumor um and the sort of

sector council has done you know from

ruin health and welfare group and and

health welfare board with the VMD to get

messages out but actually this is

everyone's responsibility. So this is

about government but also private

practice and farmers taking

responsibility that we actually use the

evidence which we've got in actually

reducing misunderstandings to get a

really major team effort without working

together. We're not going to actually

deal with the kind of the whole range of

disease threats on our borders that the

clar just described. So c we can do more

cap. I think we can definitely do more

in making sure we reinforce at every

opportunity. It's every farm visit. It's

every discussion. It's using vehicles

like the pathway that are out there in

England where we're actually on farm

talking about preventative messages. So

I think there's a massive opportunity to

to to do that because also surveillance

is about teamwork. It's about sharing

data. It's about basically you know

making sure we flag those early warning

signs and observations. So, you know,

every single farm, every single farmer

vet discussion, every opportunity we've

got is important here in both messaging

about prevention, but also making sure

we get the data we need for our overall

kind of trade discussions and the early

warning alerts. So, massive team effort,

I think, is is key here.

>> Okay. And Gavin, you're you're probably

on the panel, you're probably the one

that's sitting closest to the consumers

as well.

um and understanding you know consumer

attitudes around all of this. So I was

just wondering

do you think consumers understand what

we're doing and you know the way that we

farm and you know the fundamental role

>> it's quite a question really to be

honest it really is um I think the

perception is is yes but

but

um there's interesting things for instance

the recent big euthanasia and welfare

issues on farm that all over the press

really didn't do any damage to pork

sales. So there there is a piece within

the public about how they view

many of the aspects around uh animal

welfare, animal health production,

antibiotics etc. Um

there are very very vocal anti-meat

groups out there which which most of us

have sort of been exposed to very much

against meat very much against intensive

farming and I think that's always an

interesting one you know the definition

around intensive farming

um you know intensive farming should and

could can and should allow for you know

significant positives rather than it

being an implied negative.

you know, you put good resources in for

biocurity, housing, feed, genetics,

vaccine programs, you do everything

that's right, you know, focused together

that should ensure best, you know, best

animal welfare and best animal health at

scale. Um, and therefore hopefully

associated with a low antibiotic use,

you know, to go along with that. I I

don't think that message perhaps is

shouted about um or or perhaps not

explained that that well possibly

because every now and again there's a

little bump in the road that comes up

and that grabs the press and all the

other good work perhaps gets,

you know, not forgotten about, but it's

it's it's it's harder to show it again.

So, you know, I think big, you know, is

not by default bad. It shouldn't that

shouldn't be the case. It should be

good. It can be very good. Can be very

efficient. Um

I think maybe that does need messaging

more. I think it's been really

interesting with the response to um

Clarkson's farm.

You know, so many people are talking

about it and and continue to talk about

it. It's like, oh, we never knew, you

know, that was that happened in farming.

And it's been received in a very

positive way. I think you know it's done

a really good thing you know something

like that that that maybe shows a little

bit more of intensive farming bigger

scale farming and actually tries to show

all those things I mentioned before the

efficiencies that can go in to make this

a you know can make it a very high

quality thing um I think there was a

thought somewhere around about perhaps

should consumers perhaps be more aware

of some of the legislation or perhaps

particularly the veterary medicine's

regul regulations. But I have to be

honest and it's probably been this way

for a long time. An awful lot of surveys

show with consumers for retailers and

food service. You know, actually the the

the significant trust by consumers is

actually directly with their retailer

and their and their um food service

companies. You know, they trust them

that the surveys keep coming back and

and the level of trust is is very very

high. um they are you know they're

trusted to do it right. So I think

that's an interesting way for us then

maybe to think about is is well okay if

that consumer trust is there how do we

all put that bit to make sure that those

retailers and food services have all the

tools the information data that they

need to be able to keep doing the things

that they do and keep the consumer you

know trusting what they do. So I think

you know extending that you know most

retailers and food service um a lot are

all members of FIA food industry

initiative on antimicrobials

you know they operate to you know a

collective uh position and purpose on on

policies supporting you know responsible

use of antibiotics

you know and those members have been

really aligned. They have been very

aligned and and to a pretty good extent

been very non-competitive.

You know, it's been a very positive

environment. They all want the same the

same thing. But that lack of ruminant

usage data now is is sort of putting

that at risk. You know, retailers

genuinely under say about where the the

pressure comes in the system. It's it's

it is consumers but a lot of the

retailers are under pressure from you

know external sources you know uh and

shareholder pressure etc on their boards

to be able to demonstrate and show that

they are doing animal health and welfare

properly including antimicrobial usage

you know so you know it' be a real

missed opportunity I think for for for

the sector that we're really talking

about or I am really for the ruminant

bit at the moment you know to risk

missing not helping that joined up

approach. You know I if we if we miss

that you know it's going to look

different because the retailers are in

that position now of going we need this

data now. You know we've we've gone

along for quite a long time staying

together being being a a non-competitive

joined up voice but the risk is you know

they're under significant business

pressure and they they could easily go

off and do do different things. So

I think that's just critical that you

know that is supported that in that

supply chain that the retailers and the

food service are such a massive you know

uh user of meat milk

supply chain products from the farming

sector and then you put export on that

as well.

there's two huge areas that are really

needing and wanting this information and

they want to show they want to show the

positives. Um, so yeah, I think there

there is consumer pressure. It's it's

nuance sometimes. I think sometimes when

price comes in, you know, it's a natural

thing. You know, financial difficulties,

people perhaps don't push

some of the aspects so much. But I think

people are aware of it. But I think we

we as a sector entirely could could

genuinely show that there's a lot more

good stuff.

>> And Abby, I was I was thinking the other

day um about the the evolution that that

Rumor went through from when I first got

involved with it back in 2006, whenever

it was, to to where we are now. And part

of that evolution um back in

2014, I think it was where we we started

being a lot more

um focusing in on our targets, looking

at our, you know, the way that Ruma

worked, the way we pulled the industry

together, the way that we worked a lot

closer and collaboratively with, you

know, with the likes of the VMD, um FSA,

all like that. A lot of that was in

response to some of the pressure that we

were getting from retailers, from MEPs,

from MEPs in Europe as well.

As as the regulator, Abby, do you

do you think that we we've done the

right thing? And is there more that that

we need to keep doing or are we just

doing, you know, do we keep doing what

we're doing to continue getting and

gaining the confidence of you as a

regulator in our responsible use principles?

Thanks, K. I mean, I personally um value

collaboration. I think the VMD now uh

champions collaboration as a regulator,

which is actually maybe a little bit

unique. uh as others tell me although I

feel that it is a way of working that is

really important and I think the

increased knowledge of each partner

stakeholder customer whatever we might

want to call ourselves to each other um

knowledge of our feeling on our ambition

on something our ability to deliver a

thing especially when that thing is in um

an agreed uh vision for what the future

should look like um is really important

and I don't think that we can ever stop

wanting to collaborate. I don't think we

ever should stop collaborating. um and

the more we know about what each other

is doing and the challenges and you know

I don't want to talk about the vaccine

strategy too much because I know we've

got another session on that but that has

been a really good example of where

we've led on understanding what those

pinch points are where are the issues

because if there is something then that

we can understand from each sector's

point of view

um we can then address that I think that

also the value of having those open

conversations and working

collaboratively is that we can see where

there is ambition and we can see where

there has been really great progress and

we know how much you know advance we

have made over the last um uh 10 or 12

years. Um so absolutely I think that

there is a space to continue working in

the way that we have um and as we do so

we will have a greater understanding of

of what can be delivered what has been

delivered but what also some of those

challenges that we've got ahead of us

look like

>> and then Carl can I just um just

basically to kind of take us around the

globe a little bit you know and broaden

out kind of European consumers um what's

what's your perception and

you know kind of what do what do you see internationally?

internationally?

Do you think that the UK is a more

sensitive approach to how we treat

animals? Are we are we working along the

same principles doing things slightly

differently? What's what's your take?

>> Um I I think the UK is working on the

same principles. I think you uh and God

it's a pity this is being taped because

I'll be on record now saying something I

probably regret now. I think you have a slightly

slightly

overexited media environment. Can I say

it that way? Um, which makes that cool,

calm scientific decision-m is sometimes

a little bit uh challenged. Thankfully,

happily, I think in the UK there is

cool, calm and scientific based

decision-m, but it is under pressure.

But, but that's a threat that that

decisions should not be made under, you

know, the the the the

threat of some sort of, you know, media

article or frenzy or whatever it is. So,

that's one difference I definitely see.

I don't see the frenzies the same way in

other places. I also think that um um

in other markets there is a much I think

much greater acceptance of the wider

livestock uh uh uh community's role. Um

the the whole ecosystem um I don't think

they feel as under threat in many other

countries as I think they sometimes feel

in the UK. that might have something to

do with the first point. Uh I'm not

sure. Um

but I do feel that uh

you know there is certainly consumer

pressure to produce more sustainably. Uh

people that pressure is there. Uh all of

the accounts however show that

and all all reports and forward-looking

visions show that you know meat and milk

consumption is not going to dramatically

decrease. It's going to stay stable in

Western European uh economies and it's

going to increase quite dramatically in

other markets. Um so I think that is the

reality we we live in and the only

significant question then that remains

is how do we do that in a way which is

respecting of animal welfare respecting

of the you know more environmental more

sustainable and you know magic magic uh

better animal health there you go uh

that's the solution um better animal

health better animal welfare um

are are the motors I think are the

enablers of efficient

uh and and clean cleaner production um

and we've seen that in AMR and we've

seen that we'll see that in every other

thing and prevention but I'll come to

prevention at the end cat. >> Okay.

>> Okay. Um

just changing t then slightly again um and I'll probably come to Jonathan again

and I'll probably come to Jonathan again on this one. Do you think there are

on this one. Do you think there are opportunities to achieve more

opportunities to achieve more improvements in housing, nutrition,

improvements in housing, nutrition, biocurity to support our responsible use

biocurity to support our responsible use of medicines without compromising

of medicines without compromising productivity?

productivity? >> It's a it's a good question. I think um

>> It's a it's a good question. I think um look there's massive win-win

look there's massive win-win opportunities here. I mean disease is

opportunities here. I mean disease is waste. disease is waste in terms of you

waste. disease is waste in terms of you know food production in terms of

know food production in terms of productivity of our farming industries.

productivity of our farming industries. It's a hit on profitability

It's a hit on profitability you know farming sector is under an ever

you know farming sector is under an ever circulating round of pressures with the

circulating round of pressures with the geopolitical aspects we talked around

geopolitical aspects we talked around already let alone uncertainties in terms

already let alone uncertainties in terms of what climate change is bringing. So

of what climate change is bringing. So disease is waste, disease is preventable

disease is waste, disease is preventable opportunities

opportunities um you know for actually saving the

um you know for actually saving the costs that go together with actually um

costs that go together with actually um losses to do with you know disease

losses to do with you know disease impact. So I think the challenge is

impact. So I think the challenge is always about investments

always about investments um because pro infrastructure and

um because pro infrastructure and preventive medicines can often feel like

preventive medicines can often feel like insurance investments where you know an

insurance investments where you know an immediate disease threat in front of you

immediate disease threat in front of you triggers a response triggers treatment

triggers a response triggers treatment and therapy but that's often

and therapy but that's often after significant losses have occurred.

after significant losses have occurred. So I think the win-win here cat is

So I think the win-win here cat is absolutely around good nutrition

absolutely around good nutrition supports good immunity you know with our

supports good immunity you know with our kind of kept you know animals it's so

kind of kept you know animals it's so important in terms of making sure we've

important in terms of making sure we've got resilience to disease from our kind

got resilience to disease from our kind of you know herds and flocks in the same

of you know herds and flocks in the same way you know good housing and management

way you know good housing and management provides an environment where clean air

provides an environment where clean air good drainage and good hygiene reduce

good drainage and good hygiene reduce the threat of disease good bio security

the threat of disease good bio security in both global trading breeding

in both global trading breeding practices in terms of those exotic

practices in terms of those exotic threats that Clara talked about, but

threats that Clara talked about, but also everyone's farm boundary. You know,

also everyone's farm boundary. You know, what we can do in terms of purchase

what we can do in terms of purchase stock, in terms of our gateways, in

stock, in terms of our gateways, in terms of our fences, we can keep disease

terms of our fences, we can keep disease out. They all reduce the waste of

out. They all reduce the waste of disease. But the things that we can also

disease. But the things that we can also do is that we can invest in vaccines and

do is that we can invest in vaccines and preventative medicines. And by doing

preventative medicines. And by doing that in a farmspecific way, by doing

that in a farmspecific way, by doing that in a way where we are prioritizing

that in a way where we are prioritizing those investments at farm level that we

those investments at farm level that we are making sure that we're picking the

are making sure that we're picking the right investments to make for each farm.

right investments to make for each farm. We're going to reduce that productivity

We're going to reduce that productivity hit and make sure there's the best

hit and make sure there's the best return on those medicine investments,

return on those medicine investments, but also those boundary purchase stock

but also those boundary purchase stock and nutrition investments that are

and nutrition investments that are important. So, I think I think there's a

important. So, I think I think there's a win-win here, Cat. I think there really

win-win here, Cat. I think there really is that by doing those things that

is that by doing those things that improve resilience to disease, they

improve resilience to disease, they actually enhance productivity. Um, and

actually enhance productivity. Um, and part of that is definitely using the

part of that is definitely using the vaccines which reduce not just exotic

vaccines which reduce not just exotic disease threats, but those key endemic

disease threats, but those key endemic diseases that really rob us of

diseases that really rob us of productivity. And I'm I'm going to pick

productivity. And I'm I'm going to pick the obvious one in terms of BVD and

the obvious one in terms of BVD and cattle because it's the one I'm kind of

cattle because it's the one I'm kind of closest to. But you know, we've got an

closest to. But you know, we've got an imunosuppressive disease which basically

imunosuppressive disease which basically opens up animals to, you know, lots and

opens up animals to, you know, lots and lots of other more severe diseases. And

lots of other more severe diseases. And until we've got rid of that, we

until we've got rid of that, we basically we're carrying a millstone

basically we're carrying a millstone around that makes everything else

around that makes everything else harder. And when we've got programs like

harder. And when we've got programs like the animal health and welfare pathway

the animal health and welfare pathway that are actually funding

that are actually funding farmer and vet specific planning

farmer and vet specific planning then actually we've got a lot of the

then actually we've got a lot of the tools here to put those win-wins into

tools here to put those win-wins into place. So I think farm specific herd

place. So I think farm specific herd health block health planning you know

health block health planning you know using structures like the pathway in

using structures like the pathway in England but also great programs in in

England but also great programs in in Scotland in Wales and Ireland. we can do

Scotland in Wales and Ireland. we can do these things in a way that actually

these things in a way that actually enhance productivity and protect

enhance productivity and protect profitability because the wasted disease

profitability because the wasted disease is the biggest cost in this I

is the biggest cost in this I >> and G I'm just going to come to you I

>> and G I'm just going to come to you I was I was very struck by Jonathan with

was I was very struck by Jonathan with his disease is waste I think it's a

his disease is waste I think it's a really nice little sound bite and you

really nice little sound bite and you know kind of from your side obviously

know kind of from your side obviously you know when you start and talk about

you know when you start and talk about waste you start and think about kind of

waste you start and think about kind of profitability productivity you know food

profitability productivity you know food security. So I just wanted to bring you

security. So I just wanted to bring you in for for your thoughts on that. Yeah,

in for for your thoughts on that. Yeah, I think you know a lot of that will will

I think you know a lot of that will will come back in you know if they're endemic

come back in you know if they're endemic disease particularly parasitic diseases

disease particularly parasitic diseases you know you're looking at effects on

you know you're looking at effects on livers etc when they come to slaughter

livers etc when they come to slaughter and that's that's potentially just

and that's that's potentially just completely wasted product and food it'll

completely wasted product and food it'll go as a byproduct

go as a byproduct um it can lose obviously lose value it's

um it can lose obviously lose value it's not going to the human food chain um for

not going to the human food chain um for domestic or export so um the I think the

domestic or export so um the I think the other factor that for me fits with this

other factor that for me fits with this as Well, which again is a big

as Well, which again is a big opportunity and it and it really links

opportunity and it and it really links into if you if you got healthy animals

into if you if you got healthy animals and you know disease is waste as

and you know disease is waste as Jonathan said, those animals are going

Jonathan said, those animals are going to grow more quickly. They're going to

to grow more quickly. They're going to finish faster. So they're they're sort

finish faster. So they're they're sort of gas emission footprint, however we

of gas emission footprint, however we want to measure it, is going to be much

want to measure it, is going to be much lower. So you you've got that additional

lower. So you you've got that additional win as well as not using antimicrobials.

win as well as not using antimicrobials. you you've got a growth win and you've

you you've got a growth win and you've got a you know an an environmental win

got a you know an an environmental win at the same time. So you

at the same time. So you it's just yeah it's just that natural

it's just yeah it's just that natural thing. It all comes together. You got a

thing. It all comes together. You got a better finished product coming into

better finished product coming into slaughter, healthier animal,

slaughter, healthier animal, >> less waste at the abattoire um and

>> less waste at the abattoire um and faster to finish. So it's it's all good.

faster to finish. So it's it's all good. Very it's very positive.

Very it's very positive. And

And and then Claraara just on to bring you

and then Claraara just on to bring you into this as well a little bit.

into this as well a little bit. What opportunities do we have from

What opportunities do we have from surveillance? Are we making the best use

surveillance? Are we making the best use of the surveillance potential

of the surveillance potential in in in the UK,

in in in the UK, you know, to try and kind of deal with

you know, to try and kind of deal with deal with um with productivity,

deal with um with productivity, profitability,

profitability, you know, food security, animal health

you know, food security, animal health and welfare.

and welfare. Um, so I I just want to reflect on um my

Um, so I I just want to reflect on um my time many years ago as a farm vet in the

time many years ago as a farm vet in the in the southwest because we really are

in the southwest because we really are with surveillance. We're so dependent on

with surveillance. We're so dependent on all of those vets and and keepers of

all of those vets and and keepers of animals and farmers out there um to

animals and farmers out there um to work together and to

work together and to the boots on the ground. you know, the

the boots on the ground. you know, the eyes and ears um uh for for all of us to

eyes and ears um uh for for all of us to be picking up on any signs or or signals

be picking up on any signs or or signals of uh disease, whether that be a exotic

of uh disease, whether that be a exotic notifiable disease report case that

notifiable disease report case that they'll phone in very quickly or a vet

they'll phone in very quickly or a vet working with a farmer on um insidious

working with a farmer on um insidious disease might be BBD that can then work

disease might be BBD that can then work with local uh APA uh colleagues, take it

with local uh APA uh colleagues, take it to the veterary investigations center

to the veterary investigations center you can work with. We've got species

you can work with. We've got species expert groups who work with vets to

expert groups who work with vets to really try to um discover what's

really try to um discover what's happening and and tackle that. So all of

happening and and tackle that. So all of that information is so valuable. um as

that information is so valuable. um as well as the sort of surveillance

well as the sort of surveillance programs that we put in place as I've

programs that we put in place as I've said for AMR. Uh, one of those is that

said for AMR. Uh, one of those is that that constant um, monitoring um, in

that constant um, monitoring um, in healthy and diseased uh, animals, but

healthy and diseased uh, animals, but uh, I think all of that information

uh, I think all of that information gathering from um, across the country

gathering from um, across the country really is so important. And as I said,

really is so important. And as I said, working with international partners to

working with international partners to understand what other countries are

understand what other countries are experiencing and and how they're

experiencing and and how they're responding um to those because we're

responding um to those because we're only as strong as our weakest animal

only as strong as our weakest animal health system. Um I'm pretty proud of

health system. Um I'm pretty proud of the animal health system that we have

the animal health system that we have here as collectively as as private vets

here as collectively as as private vets as uh APA. Um but as Abby was saying the

as uh APA. Um but as Abby was saying the importance of working with international

importance of working with international partners to support strengthening of

partners to support strengthening of their animal health systems as well. Um

their animal health systems as well. Um we um might be an island but really

we um might be an island but really we're so um reliant on others beyond

we're so um reliant on others beyond these shores um as well. Just coming

these shores um as well. Just coming back to the animal health and welfare

back to the animal health and welfare pathway if I um may um Jonathan

pathway if I um may um Jonathan highlighted this. It's a really amazing

highlighted this. It's a really amazing initiative. I'm not leading on it. I

initiative. I'm not leading on it. I don't know the details but I when I was

don't know the details but I when I was in practice I worked u there was a a

in practice I worked u there was a a precursor the Southwest healthy

precursor the Southwest healthy livestock initiative which was similar

livestock initiative which was similar in that it funded vet visits and two

in that it funded vet visits and two farms and the time I spent that the farm

farms and the time I spent that the farm wasn't paying for so there wasn't the

wasn't paying for so there wasn't the pressure on the farm going through I

pressure on the farm going through I think we were focusing on yonies uh some

think we were focusing on yonies uh some of the visits were on mastitis but it

of the visits were on mastitis but it gave us the time together to walk around

gave us the time together to walk around the farm. Really think about the issues

the farm. Really think about the issues at the farm boundary but within

at the farm boundary but within biocurity within different parts of the

biocurity within different parts of the farm and then think about adaptations

farm and then think about adaptations that worked for that particular uh farm

that worked for that particular uh farm because it's not a cookie cutter

because it's not a cookie cutter approach. Um um you need to um people

approach. Um um you need to um people will need to think about what works for

will need to think about what works for them. But being almost given that time

them. But being almost given that time to have that conversation was was so

to have that conversation was was so valuable. Um, so I'd highlight what

valuable. Um, so I'd highlight what Jonathan said about every uh

Jonathan said about every uh conversation having so much value to

conversation having so much value to really improve animal health and

really improve animal health and welfare.

welfare. >> Pat, could I add something to that?

>> Pat, could I add something to that? >> Yeah, of course. uh ju just from my

>> Yeah, of course. uh ju just from my global perspective I mean and going to

global perspective I mean and going to the question about you know improvements

the question about you know improvements in housing and and nutrition and

in housing and and nutrition and biocurity and all of those types of

biocurity and all of those types of investments that are necessary or or or

investments that are necessary or or or desirable I should say. Um,

desirable I should say. Um, I I would just from a global perspective

I I would just from a global perspective make the point that I I if I compare the

make the point that I I if I compare the UK to other countries, I I do see a lot

UK to other countries, I I do see a lot of

of dare I say more sympathy in and

dare I say more sympathy in and investment in um in other countries for

investment in um in other countries for for the wider livestock ecosystem.

for the wider livestock ecosystem. And um I I think that takes the form at

And um I I think that takes the form at least from from from the government side

least from from from the government side in all kinds it takes different forms

in all kinds it takes different forms like trying to open up export markets

like trying to open up export markets being very very proactive in trying to

being very very proactive in trying to open up export markets. Some some

open up export markets. Some some countries are very good at that or or

countries are very good at that or or putting in place vaccination policies

putting in place vaccination policies which are very predictable

which are very predictable uh so that so that farmers know um

uh so that so that farmers know um what's coming or or even co-unding

what's coming or or even co-unding vaccination. I mean your cousins uh your

vaccination. I mean your cousins uh your Gaelic cousins co-und vaccination um you

Gaelic cousins co-und vaccination um you know I'm not sure what the case is in

know I'm not sure what the case is in the UK but that's that those are very

the UK but that's that those are very proactive almost

proactive almost um policies facilitating onfarmm

um policies facilitating onfarmm investment flows tax breaks recognition

investment flows tax breaks recognition much wider kind of societal recognition

much wider kind of societal recognition of societal value of of of farming and

of societal value of of of farming and livestock these are things which I think

livestock these are things which I think really are opportunities also in the UK

really are opportunities also in the UK um um to support the wider livestock

um um to support the wider livestock community which plays not just their own

community which plays not just their own and I mean I think you said it Jonathan

and I mean I think you said it Jonathan food food food food supply but in a

food food food food supply but in a whole bunch of other areas societal

whole bunch of other areas societal values and you know community uh uh

values and you know community uh uh rural development all kinds of things I

rural development all kinds of things I think we need to look at that that full

think we need to look at that that full wide package of things in that way

wide package of things in that way >> sorry I had to interject there Cat

>> sorry I had to interject there Cat >> no it was it was a very very useful um

>> no it was it was a very very useful um interjection Carl so um so yes and I

interjection Carl so um so yes and I think it's It's

think it's It's I think this is where the the

I think this is where the the frustration comes in, doesn't it? We

frustration comes in, doesn't it? We historically we've been very good at

historically we've been very good at going into silos and trying to find

going into silos and trying to find solutions in silos and actually a lot of

solutions in silos and actually a lot of what we're talking about and a lot of

what we're talking about and a lot of what we're we're thinking it's about

what we're we're thinking it's about opening up those silos completely and

opening up those silos completely and trying to look at the the whole picture

trying to look at the the whole picture and seeing so it's not really you know

and seeing so it's not really you know an aspect being somebody's individual

an aspect being somebody's individual responsibility. It's that shared

responsibility. It's that shared responsibility, isn't it? And that's

responsibility, isn't it? And that's that's farmers, vets on the ground,

that's farmers, vets on the ground, government bodies, regulators,

government bodies, regulators, you know, parliamentary decisions,

you know, parliamentary decisions, whatever. It's it should all be it

whatever. It's it should all be it should all be taken out of the silos and

should all be taken out of the silos and and looked at in the whole, I think.

and looked at in the whole, I think. Okay, I'm going to move on and change

Okay, I'm going to move on and change tangent a little bit again. Um,

tangent a little bit again. Um, and I think I'm going to just basically

and I think I'm going to just basically open this up and ask any of you for an

open this up and ask any of you for an opinion. So, do you see any challenges

opinion. So, do you see any challenges to our responsible use of medicines from

to our responsible use of medicines from greater awareness or or interest on the

greater awareness or or interest on the environmental footprint from that

environmental footprint from that medicine use? Because I think that's

medicine use? Because I think that's something that's really important.

something that's really important. I might come on to Carl first.

I might come on to Carl first. Um, but then I invite the rest of you to

Um, but then I invite the rest of you to to just wave at me. Um, if you don't

to just wave at me. Um, if you don't volunteer. So Carl, you first.

volunteer. So Carl, you first. >> Yeah, I I'll keep it to the point. It's

>> Yeah, I I'll keep it to the point. It's obvious that there is a lot more

obvious that there is a lot more interest in environmental impact of

interest in environmental impact of farming. And I think Gavin, you said it

farming. And I think Gavin, you said it very clearly or maybe it was you,

very clearly or maybe it was you, Jonathan. The more efficient we can do

Jonathan. The more efficient we can do this, the healthier we keep the animals,

this, the healthier we keep the animals, the the more productivity we have. Now

the the more productivity we have. Now that's a mac from a macro

that's a mac from a macro point of view that's not that's a very

point of view that's not that's a very easy argument. From a micro point of

easy argument. From a micro point of view it's a difficult argument for some

view it's a difficult argument for some people to comprehend. Uh and I think a

people to comprehend. Uh and I think a lot more effort needs to be made from

lot more effort needs to be made from everybody

everybody to get that point across. Um so and it's

to get that point across. Um so and it's it's there's all kinds of aspects to it.

it's there's all kinds of aspects to it. um um you know antimicrobials is one but

um um you know antimicrobials is one but but but you know vaccine genetics

but but you know vaccine genetics there's all kinds of stuff I won't go

there's all kinds of stuff I won't go into now we don't have time to go into

into now we don't have time to go into now but it's obvious that as as a whole

now but it's obvious that as as a whole the wider global and UK livestock

the wider global and UK livestock community needs to do better the tools

community needs to do better the tools are there it's it's using these tools in

are there it's it's using these tools in a more efficient manner Jonathan you

a more efficient manner Jonathan you talked about a couple of diseases where

talked about a couple of diseases where you could you could you know if if you

you could you could you know if if you treated those or prevented those then

treated those or prevented those then you could have a great great impact. So

you could have a great great impact. So I'll I'll leave it at that.

I'll I'll leave it at that. >> Can I can I come this comment? I think

>> Can I can I come this comment? I think following on from what what Carol's

following on from what what Carol's saying and there's a couple of thoughts

saying and there's a couple of thoughts really. I think the first thing is

really. I think the first thing is environmental footprint means lots of

environmental footprint means lots of different things. You know we we we've

different things. You know we we we've talked about you know the broad aspects

talked about you know the broad aspects of impacts interactions that are warming

of impacts interactions that are warming they are you know biodiversity they're

they are you know biodiversity they're land use change their water you know. I

land use change their water you know. I think we just need to be quite clear

think we just need to be quite clear about actually what environmental sort

about actually what environmental sort of impacts and footprints mean. So the

of impacts and footprints mean. So the first thing is that you know the disease

first thing is that you know the disease is waste aspect is never true as Gavin

is waste aspect is never true as Gavin talked about in terms of efficiencies of

talked about in terms of efficiencies of production. You know if we can improve

production. You know if we can improve what daily live weight gain is you know

what daily live weight gain is you know mobilizing the immune system to fight

mobilizing the immune system to fight disease burns megajoules you know it

disease burns megajoules you know it reduces basically efficiencies of

reduces basically efficiencies of production. It therefore reduces how

production. It therefore reduces how much food we we actually kind of are

much food we we actually kind of are able to produce on farm per you know ton

able to produce on farm per you know ton of carbon. So there's actually a very

of carbon. So there's actually a very very clear benefit where we can just

very clear benefit where we can just trade off the return on investment for

trade off the return on investment for the environment by actually better

the environment by actually better health. So I think that's really really

health. So I think that's really really clear. We've got good numbers on that.

clear. We've got good numbers on that. We've got good metrics. The evidence is

We've got good metrics. The evidence is incredibly strong. I think it can be

incredibly strong. I think it can be harder if we've got um aspects of

harder if we've got um aspects of residues that might impact you know both

residues that might impact you know both our water quality, soil quality and hit

our water quality, soil quality and hit biodiversity

biodiversity and I think responsible use is in my

and I think responsible use is in my view very much about precision then you

view very much about precision then you know can we make better use of

know can we make better use of diagnostics so that we're using the

diagnostics so that we're using the right products at the right times for

right products at the right times for the right farm and can we use things in

the right farm and can we use things in a more precise way you know reduce

a more precise way you know reduce blanket use we've moved away from

blanket use we've moved away from prophylactic use of antimicrobials

prophylactic use of antimicrobials um to much more targeted use and I think

um to much more targeted use and I think that applies to things like you know

that applies to things like you know wormers and lots of other parasitices

wormers and lots of other parasitices where if we've got precision use we

where if we've got precision use we really will reduce a lot of the impact

really will reduce a lot of the impact on the environment but we've got to

on the environment but we've got to remember animal welfare is really

remember animal welfare is really important and therefore you know this is

important and therefore you know this is about using as little as we as we can

about using as little as we as we can you know as we need as little as we can

you know as we need as little as we can but as much as we need and I And that's

but as much as we need and I And that's really important to recognize. So

really important to recognize. So precision is is I think important in

precision is is I think important in managing residue risks and managing

managing residue risks and managing those wider things. We need the

those wider things. We need the products, but we should use them in a

products, but we should use them in a precise way.

precise way. >> Thank you. Um Abby, yes, please come in.

>> Thank you. Um Abby, yes, please come in. >> Yeah, thanks C. I mean I just want to

>> Yeah, thanks C. I mean I just want to say I mean I know I know you all know

say I mean I know I know you all know this but just for the record obviously

this but just for the record obviously over the years uh that we we undertake

over the years uh that we we undertake our um assessments of medicine

our um assessments of medicine applications of course what we conduct

applications of course what we conduct as part of that robust benefit risk

as part of that robust benefit risk analysis is um a risk assessment of the

analysis is um a risk assessment of the environmental impact um and especially

environmental impact um and especially in um medicines that are destined for

in um medicines that are destined for for livestock for the food u producing

for livestock for the food u producing species that that goes through uh two

species that that goes through uh two phases of um environmental consider

phases of um environmental consider erations and when there has been a risk

erations and when there has been a risk that's been identified, those

that's been identified, those environmental warnings obviously and

environmental warnings obviously and mitigation measures are included in the

mitigation measures are included in the in the packaging on on the on the leaf

in the packaging on on the on the leaf and label. But I do recognize that there

and label. But I do recognize that there is an increased interest in

is an increased interest in environmental um factors and it's not a

environmental um factors and it's not a new thing that we're suddenly looking at

new thing that we're suddenly looking at uh but has been there for quite some

uh but has been there for quite some time. um the the VMD um established uh I

time. um the the VMD um established uh I can't remember when now but over a year

can't remember when now but over a year ago the pharmaceuticals and the

ago the pharmaceuticals and the environment group which brings together

environment group which brings together across across government actually and

across across government actually and across um sectors um folk who will have

across um sectors um folk who will have an interest in uh looking at where there

an interest in uh looking at where there are residues in the environment and what

are residues in the environment and what impact that could have the angle that

impact that could have the angle that Jonathan was just referring to is really

Jonathan was just referring to is really important that we don't go down the

important that we don't go down the route of saying environmental impacts

route of saying environmental impacts are so severe that we should stop using

are so severe that we should stop using products. That's not what we're saying.

products. That's not what we're saying. The animal health and welfare aspect of

The animal health and welfare aspect of it is really important. Currently the

it is really important. Currently the the the pharmaceuticals and environment

the the pharmaceuticals and environment pie group is focusing on small animal

pie group is focusing on small animal medicines. That's where there had been

medicines. That's where there had been the most concern but obviously the

the most concern but obviously the future activities could could could go

future activities could could could go beyond that. The other thing I just

beyond that. The other thing I just wanted to say on the AMR angle is

wanted to say on the AMR angle is obviously you know it's really important

obviously you know it's really important that we think about those environmental

that we think about those environmental dimensions because that's why we take

dimensions because that's why we take that one health approach. Um and um you

that one health approach. Um and um you know that's part that is that is the

know that's part that is that is the national action plan. It is one health.

national action plan. It is one health. We know that that resistant bacteria can

We know that that resistant bacteria can spread from animals to people and people

spread from animals to people and people to animals and through the environment.

to animals and through the environment. And I think an increased understanding

And I think an increased understanding of that through an interest perhaps in

of that through an interest perhaps in the environmental impacts um is really

the environmental impacts um is really of benefit to us to enable responsible

of benefit to us to enable responsible use enable um limited impact on the

use enable um limited impact on the environment but to protect animal health

environment but to protect animal health and welfare.

and welfare. >> Thanks. Thank you. Now we've got we've

>> Thanks. Thank you. Now we've got we've got got one more question to put to to

got got one more question to put to to you. Um and again I'd like time for all

you. Um and again I'd like time for all of you to to come in on that one. Um

of you to to come in on that one. Um just so before we come on to that that

just so before we come on to that that question

question I just want to remind people to sign up

I just want to remind people to sign up to the rest of the the webinars. Um, I

to the rest of the the webinars. Um, I think there will be a booking link will

think there will be a booking link will shortly be posted on the the Q&A to

shortly be posted on the the Q&A to this, but I just wanted to just remind

this, but I just wanted to just remind people um to please sign up and register

people um to please sign up and register for the for the later webinars.

for the for the later webinars. And as I said before, all webinars will

And as I said before, all webinars will be available to re-watch on our website

be available to re-watch on our website um in the near future.

um in the near future. So, my final question to all of you, and

So, my final question to all of you, and you've been a great panel so far, um so

you've been a great panel so far, um so don't let me down. Come up with some

don't let me down. Come up with some good answers.

good answers. What single change would have the

What single change would have the biggest long-term impact on keeping

biggest long-term impact on keeping medicines effective for both animals and

medicines effective for both animals and people?

people? Um Gavin, I'm going to come to you

Um Gavin, I'm going to come to you please.

I think it might be interesting to look at

think it might be interesting to look at I think it's from the point that many

I think it's from the point that many farmers are very engaged with this and

farmers are very engaged with this and lots of people in the chain are um but

lots of people in the chain are um but potentially others maybe perhaps just

potentially others maybe perhaps just don't necessarily know what they don't

don't necessarily know what they don't know. Um but that way there's a there's

know. Um but that way there's a there's a lot of information in and around this

a lot of information in and around this whole topic. So, I just wonder whether

whole topic. So, I just wonder whether some form of uh perhaps a a national

some form of uh perhaps a a national or health and welfare responsible use

or health and welfare responsible use training program could possibly have

training program could possibly have quite a significant benefit. Bring

quite a significant benefit. Bring everybody everybody up to a level of

everybody everybody up to a level of knowledge on this on this topic. um how

knowledge on this on this topic. um how that would be delivered, possible

that would be delivered, possible mechanisms, but but yeah, I'd just be

mechanisms, but but yeah, I'd just be interested to explore that to see that

interested to explore that to see that there was a a program that everyone who

there was a a program that everyone who farmed livestock had to do in whatever

farmed livestock had to do in whatever shape that took.

shape that took. >> Okay.

>> Okay. Interesting concept. Um

Interesting concept. Um >> you asked for something different.

>> you asked for something different. >> I did. Yes, I did. [laughter]

>> I did. Yes, I did. [laughter] I'll go with you next just in case.

I'll go with you next just in case. Thank you. I I really think that focus

Thank you. I I really think that focus on disease prevention is the is the

on disease prevention is the is the first step um uh through improved

first step um uh through improved biocurity, vaccination, uh surveillance,

biocurity, vaccination, uh surveillance, but really doing that through teamwork

but really doing that through teamwork um to whether that's to prevent and

um to whether that's to prevent and respond to exotic notifiable disease or

respond to exotic notifiable disease or really working closely with your um vets

really working closely with your um vets on tackling endemic disease. and uh and

on tackling endemic disease. and uh and APA is a really integral part of that

APA is a really integral part of that team. It might be locally getting to

team. It might be locally getting to know your local vet investigation center

know your local vet investigation center or APA um vets or international

or APA um vets or international partnerships really learning from each

partnerships really learning from each other and and how we tackle that. But

other and and how we tackle that. But I'd really want to focus on prevention.

I'd really want to focus on prevention. >> Okay.

>> Okay. And I'll come to Abby I think next to

And I'll come to Abby I think next to answer please.

answer please. >> Thanks C. I was think I was trying to

>> Thanks C. I was think I was trying to think of something really dramatic u but

think of something really dramatic u but unfortunately rather boringly I think

unfortunately rather boringly I think I'd follow on uh very succinctly from

I'd follow on uh very succinctly from what Claraara was saying because I think

what Claraara was saying because I think the there's not necessarily a single

the there's not necessarily a single change I think there's an enhancement

change I think there's an enhancement and and a continuation of what we're

and and a continuation of what we're currently doing and maybe the theme that

currently doing and maybe the theme that we've talked about today around

we've talked about today around collaboration around the importance of

collaboration around the importance of having really great surveillance about

having really great surveillance about having really great data that helps

having really great data that helps inform us whether or not uh the

inform us whether or not uh the medicines that are currently being used

medicines that are currently being used are effective and if not what can we do

are effective and if not what can we do about that that will help increase that

about that that will help increase that um uh ambition to have um safe and

um uh ambition to have um safe and effective medicines available but in as

effective medicines available but in as I've said before you know working

I've said before you know working together to understand what the pinch

together to understand what the pinch points would be and that is through that

points would be and that is through that collaboration and we've already put that

collaboration and we've already put that in train so I suppose a change would be

in train so I suppose a change would be increasing

increasing um the the number of people who are

um the the number of people who are working in that space and thinking in

working in that space and thinking in that collaborative way and bringing

that collaborative way and bringing everybody along on that journey um I

everybody along on that journey um I think there's probably some little bits

think there's probably some little bits of innovation we can do around um

of innovation we can do around um surveillance um and stewardship that may

surveillance um and stewardship that may well help um to uh very specifically but

well help um to uh very specifically but I think overall data and people is

I think overall data and people is really key.

really key. >> Okay.

>> Okay. And who wants to go next?

And who wants to go next? >> I'll go.

>> I'll go. >> I'll go.

>> I'll go. >> Thanks Carl.

>> Thanks Carl. >> Um so so you asked Cap what single

>> Um so so you asked Cap what single change would have the biggest long-term

change would have the biggest long-term impact? So I'm going to give you two

impact? So I'm going to give you two answers. Okay.

answers. Okay. >> Uh the negative one is a massive

>> Uh the negative one is a massive preventable outbreak of something which

preventable outbreak of something which would really really negative and you you

would really really negative and you you guys have gone through it in the UK

guys have gone through it in the UK already. I won't remind you of the

already. I won't remind you of the disease. Uh but that led to the most

disease. Uh but that led to the most changes in in in I think in in in

changes in in in I think in in in livestock uh keeping and and stuff for

livestock uh keeping and and stuff for 20 or 30 years. So unfortunately it's a

20 or 30 years. So unfortunately it's a it's it's an outbreak I think of

it's it's an outbreak I think of something which was preventable and now

something which was preventable and now let me get to the positive one which is

let me get to the positive one which is building on what what I think everybody

building on what what I think everybody has said right now is to prepare for

has said right now is to prepare for that and to prevent that uh and what is

that and to prevent that uh and what is needed for that is is a quite

needed for that is is a quite fundamental mind shift change

fundamental mind shift change uh toward prevention and when I say

uh toward prevention and when I say fundamental I mean through government

fundamental I mean through government through consumer through farmer to the

through consumer through farmer to the entire chain really beginning to think

entire chain really beginning to think much harder and act much faster on

much harder and act much faster on prevention

prevention uh and putting in place what prevention

uh and putting in place what prevention actually is um so that you don't have

actually is um so that you don't have one of those horrible outbreaks uh which

one of those horrible outbreaks uh which you have so a fundamental mind shift

you have so a fundamental mind shift change uh toward prevention is what I

change uh toward prevention is what I would say

would say >> okay

>> okay Jonathan

Jonathan >> so I think there's lots of good stuff

>> so I think there's lots of good stuff there. I'm not sure going last is a good

there. I'm not sure going last is a good idea when there's been lots of kind of

idea when there's been lots of kind of good ideas, but uh I think what I

good ideas, but uh I think what I honestly think the single change that

honestly think the single change that had the biggest long-term impact, it

had the biggest long-term impact, it draws together a lot of those other

draws together a lot of those other answers. So forgive me therefore sort of

answers. So forgive me therefore sort of uh um take it from them but I honestly

uh um take it from them but I honestly think it would be a new normal in

think it would be a new normal in working together effectively because

working together effectively because there's a lot of sound bites but

there's a lot of sound bites but actually turning words into a new

actually turning words into a new structure a new collaborative way of

structure a new collaborative way of working and by that I mean definitely

working and by that I mean definitely industry and government so that's

industry and government so that's farmers vets pharmaceutical industry

farmers vets pharmaceutical industry government actually genuinely finding

government actually genuinely finding new ways to work together to prevent

new ways to work together to prevent those sort of outbreaks that Carl talked

those sort of outbreaks that Carl talked about and also

about and also um recognizing really what that needs to

um recognizing really what that needs to do. So a new normal okay basically how

do. So a new normal okay basically how we do those things together and I'm

we do those things together and I'm going to just if I can just pick two

going to just if I can just pick two kind of examples. So one is definitely

kind of examples. So one is definitely that prevention is better than cure

that prevention is better than cure piece. I couldn't agree more. That is

piece. I couldn't agree more. That is effective herd health. The animal health

effective herd health. The animal health and welfare strategy came out of 2001

and welfare strategy came out of 2001 footmouth outbreak and we forget the

footmouth outbreak and we forget the lessons of that at our peril.

lessons of that at our peril. the public accounts committee report are

the public accounts committee report are really going back to that discussion.

really going back to that discussion. But the other thing for me, the new

But the other thing for me, the new normal working together is actually

normal working together is actually turning the one health soundbar into

turning the one health soundbar into something that's real. You know, one

something that's real. You know, one health is about human, animal, and

health is about human, animal, and environment interactions in a balanced

environment interactions in a balanced way, not one-sided health. And I think

way, not one-sided health. And I think if we look at the way that veteran

if we look at the way that veteran medicines hasn't interacted effectively

medicines hasn't interacted effectively with billions of pounds of investment in

with billions of pounds of investment in life sciences in the way that we have a

life sciences in the way that we have a separate conversation about the

separate conversation about the environment from we do about pandemic

environment from we do about pandemic preparedness. I think the new normal for

preparedness. I think the new normal for me has got to be about finding ways to

me has got to be about finding ways to have human health, prosperity, animal

have human health, prosperity, animal health, welfare, food production and the

health, welfare, food production and the environment working together in a really

environment working together in a really functionally effective way.

functionally effective way. Okay, thank you. Well, look, thank you

Okay, thank you. Well, look, thank you so much. That's me got to the end of my

so much. That's me got to the end of my questions. I think it's been a really

questions. I think it's been a really great discussion. Thank you as a panel.

great discussion. Thank you as a panel. You've been absolutely brilliant. Um,

You've been absolutely brilliant. Um, and you know, kind of it's I think it's

and you know, kind of it's I think it's I hope everyone in the audience um has

I hope everyone in the audience um has has really enjoyed it. Um I'll just

has really enjoyed it. Um I'll just remind you again we've got um three more

remind you again we've got um three more webinars um coming up on consecutive

webinars um coming up on consecutive weddednesdays in November. So we've got

weddednesdays in November. So we've got future for vaccine availability for the

future for vaccine availability for the UK animal health market next Wednesday

UK animal health market next Wednesday same time starting at 11:00. Then we've

same time starting at 11:00. Then we've got the um rumor TTF2 final report and

got the um rumor TTF2 final report and the BMD's barge report launch on

the BMD's barge report launch on Wednesday the 19th starting again 11:00

Wednesday the 19th starting again 11:00 going on till 12:30 and then the final

going on till 12:30 and then the final webinar is the rumor TTF3 launch and

webinar is the rumor TTF3 launch and that's looking at the the unveiling of

that's looking at the the unveiling of the third cycle sector targets. That's

the third cycle sector targets. That's Wednesday the 26th of November again

Wednesday the 26th of November again 11:00 to 12:30. Um

11:00 to 12:30. Um I don't think you've actually been able

I don't think you've actually been able to see the Q the Q&A section as the

to see the Q the Q&A section as the audience but all of the registration

audience but all of the registration details are on the Rooma website. Um so

details are on the Rooma website. Um so please please do go and um and register

please please do go and um and register and at that I will thank you all very

and at that I will thank you all very much um both as a panel and as the

much um both as a panel and as the audience for giving us some time and

audience for giving us some time and actually kind of um getting involved

actually kind of um getting involved today. And I think at that I will call

today. And I think at that I will call the meeting to a close. Thank you all.

Click on any text or timestamp to jump to that moment in the video

Most transcripts ready in under 5 seconds

One-Click Copy125+ LanguagesSearch ContentJump to Timestamps

Paste YouTube URL

Enter any YouTube video link to get the full transcript

Most transcripts ready in under 5 seconds

Get Our Chrome Extension

Get transcripts instantly without leaving YouTube. Install our Chrome extension for one-click access to any video's transcript directly on the watch page.

Add to Chrome — Free

Works with YouTube, Coursera, Udemy and more educational platforms

Get Instant Transcripts: Just Edit the Domain in Your Address Bar!

YouTube

←

→

↻

https://www.youtube.com/watch?v=UF8uR6Z6KLc

YoutubeToText

←

→

↻

https://youtubetotext.net/watch?v=UF8uR6Z6KLc

YouTube TranscriptPreparing your results…

YouTube Transcript:RUMA Agri Webinar 1 2025 Opportunities & Challenges Influencing the Responsible use of Medicines